Trial | NCT01104935  Report issue

Title

National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]
Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    trastuzumab ...

  • Study Participants

    275
To investigate clinical positioning between trastuzumab (Herceptin) monotherapy (H group) and combination therapy of trastuzumab and chemotherapy (H+CT group) based on a randomized controlled trial in women over 70 years with human epidermal growth factor receptor type-2 (HER2) positive primary breast cancer.
This study is a randomized, comparative trial of postoperative adjuvant therapies in women with HER2 (human epidermal growth factor receptor type-2)-positive primary breast cancer who are ≥70 years of age that will compare trastuzumab (Herceptin®) monotherapy (H group) and trastuzumab in combination with chemotherapy (H+CT group).

The objectives of this study are as follows.

To verify the clinical positioning of trastuzumab monotherapy and combined trastuzumab and chemotherapy as postoperative adjuvant therapies for the treatment of HER2-positive primary breast cancer patients who are ≥70 years of age.
To evaluate the safety of trastuzumab monotherapy and combined trastuzumab and chemotherapy in patients who are ≥70 years of age. In particular, to evaluate cardiac disorders that are a characteristic adverse drug reaction of trastuzumab as well as geriatric-related concerns including lipid metabolism, cerebral infarction and cognitive disorders.
To evaluate overall survival in patients who are ≥70 years of age using trastuzumab monotherapy or combined trastuzumab and chemotherapy.
To evaluate health-related quality of life (HRQOL), cost-effectiveness (utility), and conduct a comprehensive geriatric assessment (CGA) in patients who are ≥70 years of age and using trastuzumab monotherapy or combined trastuzumab and chemotherapy.
To establish and expand information networks by the participation of practitioners in clinical trials that are involved in general clinical practice and breast cancer.
Study Started
Oct 28
2009
Primary Completion
Oct 31
2017
Study Completion
Oct 15
2018
Last Update
Oct 21
2019

Drug trastuzumab monotherapy

  • Other names: Herceptin

Drug trastuzumab and chemotherapy

  • Other names: PTX, DTX, TC, AC, EC, FEC, CMF, TCb (CBDCA)

trastuzumab monotherapy Experimental

H group (trastuzumab monotherapy group) Trastuzumab: 1-year treatment Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times

trastuzumab and chemotherapy Active Comparator

H+CT group (combination therapy of trastuzumab and chemotherapy) Chemotherapy: 12 to 24 weeks Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration.

Criteria 

Inclusion Criteria:

Histologically diagnosed as invasive breast cancer and received curative operation for primary breast cancer.
Stage: 1 (tumor size [pT] > 0.5 cm), 2A, 2B or 3A/ M0
Female between 70 and 80 years old
Primary region is HER 2 positive: either 3+ overexpression by IHC or positive by FISH
Baseline left ventricular ejection fraction (LVEF) is ≥55% measured by echocardiography or MUGA scan within 4 weeks before registration.
PS: 0-1 (ECOG)

Sufficient organ function meeting following criteria within 4 weeks before registration:

Leukocyte ≥2500 mm3
Neutrophil ≥1500 mm3
Platelet ≥100 000 mm3
Serum total bilirubin ≤2.0 x upper limit of normal (ULN)
ALT (GPT) or AST (GOT) ≤2.5 x ULN
Serum creatinine ≤2.0 x ULN
ALP ≤2.5 x ULN
No previous endocrine therapy or chemotherapy for breast cancer
Signed written informed consent

Exclusion Criteria:

Active multiple primary cancer (synchronous multiple primary cancer and invasive cancer of other organs)
Postoperative histological axillary lymph node metastasis ≥4
Axillary lymph node is not histologically evaluated
Histologically confirmed positive margin in breast conservation surgery (evaluation of margin status is based on policy of site)
History of drug-related allergy which could hinder planned treatment

Any history or complication of following cardiac disorders

History of congestive heart failure, cardiac infarction
Complication requires treatment such as: ischemic cardiac disorder, arrhythmia, valvular heart disease
Poorly controlled hypertension (ex. Systolic arterial pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg)
Poorly controlled diabetes
Continuous visit to a medial institution is considered difficult due to deterioration of activity of daily living (ADL)
Difficult to participate in the trial because of psychiatric disorder or psychiatric symptoms
Ineligible to the trial based on decision of an investigator
No Results Posted